Modality
Nanobody
MOA
CAR-T BCMA
Target
CFTR
Pathway
Sphingolipid
Wet AMDDravet
Development Pipeline
Preclinical
Jun 2024
→ Nov 2026
PreclinicalCurrent
NCT03483484
1,724 pts·Wet AMD
2024-06→2026-11·Active
1,724 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-11-158mo awayInterim· Wet AMD
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q4
Preclinical
Active
Catalysts
Interim
2026-11-15 · 8mo away
Wet AMD
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03483484 | Preclinical | Wet AMD | Active | 1724 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Datoglumide | AbbVie | Approved | CFTR | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| Fixatuximab | Legend Biotech | Preclinical | CFTR |